Research programme: protein kinase inhibitors - Kinexus
Alternative Names: Protein kinase inhibitors research programme - KinexusLatest Information Update: 16 Jul 2016
At a glance
- Originator Kinexus Bioinformatics Corporation
- Class
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Canada
- 28 Jul 2004 Preclinical trials in Cancer in Canada (unspecified route)